Weekly SCD Practice Update

Levagen+ Ameliorates Hyperalgesia in a Mouse Model of Sickle Cell Disease

Donovan A Argueta, Ph.D., Natalie Garcia, B.S., Yannick Fotio, Ph.D., Daniele Piomelli, Ph.D., Kalpna Gupta, Ph.D.

Key Findings

  • Purpose
    To evaluate whether palmitoylethanolamide (PEA), a non-intoxicating lipid mediator related to cannabinoid signaling, could reduce pain hypersensitivity and inflammatory activity in sickle cell disease (SCD).
  • Population (Model)

    Female humanized transgenic HbSS Berkeley (BERK) mice, a widely used model that replicates many clinical features of SCD — including chronic pain, acute pain episodes, and organ damage — were treated with oral Levagen+ for 14 days and compared with vehicle-treated controls.

  • Headline Result
    Levagen+ significantly increased circulating PEA levels and reduced mechanical, cold, and musculoskeletal hyperalgesia. Improvements were observed within one hour of treatment and continued during the 14-day dosing period. The intervention also ameliorated hypoxia-reoxygenation–induced acute hyperalgesia, improved red blood cell counts (~40%) and hemoglobin (~37%), and reduced liver enlargement.
  • Why It Matters
    Pain in SCD is often managed with opioids and other supportive therapies. This study suggests that targeting neuroimmune pathways — particularly mast cell activation and inflammatory signaling — may offer a novel non-opioid approach to chronic SCD pain management. Levagen+ also reduced circulating inflammatory markers including  ubstance P, serum amyloid P, and interleukin-6, supporting a mechanistic link between neurogenic inflammation and pain in SCD.
  • Evidence Gaps & Limitations
    The findings are preclinical and limited to a mouse model. Human clinical trials will be required to determine safety, dosing, and clinical efficacy of PEA-based therapies in patients with SCD.

Source: Journal of Sickle Cell Disease- “Levagen+ Ameliorates Hyperalgesia in a Mouse Model of Sickle Cell Disease”

Regulatory & Guideline Watch

Current American Society of Hematology (ASH) guidance emphasizes multimodal pain management in sickle cell disease, with growing interest in therapies that target inflammation, neuroimmune signaling, and disease-specific pain pathways. Translational research such as this study may help expand future non-opioid therapeutic options for chronic SCD pain.